OBJECTIVES: I. Document the clinical course of severe chronic neutropenia (SCN). II. Monitor and assess long term safety of primary treatment in SCN patients in the United States, Canada, Europe, and Australia. III. Study the incidence and outcome of adverse events such as osteoporosis, splenomegaly, cytogenetic abnormalities, myelodysplastic syndrome, and leukemia. IV. Evaluate growth and development and hematologic parameters. V. Monitor for clinically significant changes in primary treatment response over time. VI. Establish a physician network to increase the understanding of SCN. VII. Establish a demographic database to allow for future research.
PROTOCOL OUTLINE: Patients are treated by the referring physician as medically indicated. Clinical data are collected at baseline and then every 6 months.
Study Type
OBSERVATIONAL
Enrollment
1,000
Dana-Farber/Boston Children¹s Cancer and Blood Disorders Center
Boston, Massachusetts, United States
RECRUITINGUniversity of Massachusetts
Worcester, Massachusetts, United States
RECRUITINGUniversity of Michigan
Ann Arbor, Michigan, United States
RECRUITINGSt. Joseph's Children's Hospital
Paterson, New Jersey, United States
RECRUITINGUniversity of Washington School of Medicine
Seattle, Washington, United States
RECRUITINGMonash University
Melbourne, Victoria, Australia
RECRUITINGCancerCare Manitoba
Winnipeg, Manitoba, Canada
RECRUITINGHospital for Sick Children
Toronto, Ontario, Canada
RECRUITINGMedizinische Hochschule Hannover
Hanover, Germany
RECRUITINGLeeds Teaching Hospitals, Yorkshire Regional Centre for Paediatric Oncology & Haematology
Leeds, England, United Kingdom
RECRUITINGThis platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.